Sense Biodetection
Bryant Brown helped Sense Biodetection with the global launch of its Veros COVID-19 POC test…and positioned Sense for acquisition. See how!
Sense Biodetection, Veros COVID-19, COVID-19, COVID-19 point-of-care test, COVID-19 POC test, Bryant Brown Healthcare, Sherlock Biosciences, healthcare marketing, medical marketing, healthcare marketing agency, healthcare advertising, healthcare digital marketing, medical marketing companies
portfolio_page-template-default,single,single-portfolio_page,postid-25958,bridge-core-1.0.5,cookies-not-set,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.10.0,vc_responsive

Sense Biodetection

Using omnichannel marketing to drive sales
Sense Biodetection Veros COVID-19 brochure Sense Biodetection Veros COVID-19 magazine Irish Medical Times ad
About This Project


As the pandemic unfolded, Sense Biodetection developed Veros™ COVID-19. This revolutionary point-of-care (POC) diagnostic detects the virus with the speed of an antigen test (about 15 minutes) but with the accuracy of a PCR test (97.9%). Sense’s goal was to market Veros COVID-19 globally. In the process, the company also was an attractive acquisition target.



Bryant Brown Healthcare created the foundational elements of the Veros COVID-19 campaign: positioning, messaging, and branding. To help plan the media and tactics for the global launch of the product, Bryant Brown collaborated closely with UK-based healthcare communications agency Hanson Zandi Advertising.


In 2010, Bryant Brown and Hanson Zandi co-founded Encompass Worldwide, a global affiliation of agencies dedicated to healthcare marketing, advertising, and public relations. Encompass also has affiliates in the Asia-Pacific region, South America, and other regions.


Together, Bryant Brown and Hanson Zandi developed an ambitious marketing plan to promote the product—beginning in Europe, where it first received approval, then in South America. Tactics included a mix of programmatic advertising, social media promotions, email campaigns, and print advertising. Targets included healthcare specialists as well as the oil and gas industry, travel industry, educational institutions, and other potential customers.



As Veros COVID-19 launched country by country, the reception was enthusiastic. In January 2023 – before Bryant Brown Healthcare rolled out the planned US launch of the product – Sherlock Biosciences acquired Sense Biodetection.

Sherlock’s proprietary platforms for DNA and RNA detection help make rapid, accurate, and affordable diagnostic tests accessible to people at the point-of-need.